Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects, 12 to 65 years old~* Severe hemophilia B (FIX activity of ≤ 2%)~* Subjects who have received FIX products (plasma-derived and/or recombinant FIX) for \> 150 exposure days (EDs)~* No history of FIX inhibitor formation, no detectable inhibitors at Screening and no family history of inhibitors against FIX~* Written informed consent for study participation~* On-demand subjects only, who have experienced a minimum average of 2 non-trauma induced bleeding episodes requiring treatment with a FIX product during the previous 6 or 3 months~Exclusion Criteria:~* Known hypersensitivity to any FIX product or hamster protein~* Known congenital or acquired coagulation disorder other than congenital FIX deficiency~* HIV positive subjects with a CD4 count \< 200/mm3~* Low platelet count, kidney or liver dysfunction~* Recent life-threatening bleeding episode

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Prophylaxis (Type: EXPERIMENTAL): Routine weekly prophylaxis and episodic treatment for bleeding episodes. An individualized dosing interval may be tested in sub-group subjects during the 2nd part of the trial.~Subjects may participate in a surgical 'sub-study' in which rIX-FP may be administered prior to, during and after surgical intervention.
- On-demand (Type: EXPERIMENTAL): Episodic treatment for bleeding episodes during the first 6 months then switch to routine weekly prophylaxis for a further 6 months Subjects may participate in a surgical 'sub-study' in which rIX-FP may be administered prior to, during and after surgical intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).